Do you mean the Wilson’s report that valued NEU on an unrisked basis at just over $100/share?
This assumed the 4 orphan syndrome’s currently under P2 were successful in P3 trials.
Share Price, page-8135
-
- There are more pages in this discussion • 2,713 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.58 |
Change
0.720(3.63%) |
Mkt cap ! $2.626B | |||
| Open | High | Low | Value | Volume |
| $20.00 | $20.66 | $19.94 | $4.256M | 209.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 19 | $20.56 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.58 | 304 | 4 |
View Market Depth
| Last trade - 14.07pm 12/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |